BioSpace News Archive

Cerus Corporation announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer will present and provide a corporate update at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019 at 3:00 p.m. ET.

Accolade, a personalized health and benefits solution for employers, health plans and their members, announced a new Health Assistant Center in Seattle, opening in October 2019 in its new Seattle office.

Winners of the Pfizer Golden Ticket Program announced last night during a panel discussion and networking event at Pfizer’s Cambridge, MA R&D site

Cerveau Technologies, Inc. announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda), which will enable Takeda to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.

Context-Aware Packaging Is Just the Tip of the Iceberg Says Third Aurora

CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced a new collaboration with the Chattanooga Center for Neurologic Research based in Chattanooga, TN.

Citius Pharmaceuticals, Inc. announced the closing of the previously announced underwritten at-the-market offering of 7,821,230 shares of its common stock and common warrants to purchase up to an aggregate of 7,821,230 shares of Common Stock.

Robert R. Redfield, MD, the Director of the Centers for Disease Control and Prevention (CDC), will make remarks at an October 16 National Press Club Headliners Luncheon about the importance of immunization as the winter flu season is set to begin.

New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that significantly reduced the risk of disease progression by 38% compared with chemotherapy (nab-paclitaxel) alone2

Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients 2 years of age and older.